Obesity
These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long term isn’t fully known, but there are several pharmaceutical companies studying the side effect and hoping to develop therapies that might regulate the condition. In […]
Read More
‘Miracle drug’ euphoria: Specialists warn widespread use of fat decline medicine faces main hurdles
Two gurus see key difficulties facing the adoption of new being overweight medicine. Dr. Kavita Patel, a physician and NBC News health-related contributor, thinks new knowledge from Novo Nordisk on Ozempic’s means to hold off the development of long-term kidney disease is among the strongest supporting proof for secondary uses of the drug. On the […]
Read More
Will weight loss drugs lead to less food consumption? Here’s what Walmart is saying
More than 40% of adults in the U.S. are obese. That’s a big number, which makes the group a force to be reckoned with if their habits start to change suddenly. That’s why we’ve seen so many Wall Street analysts exploring the potential fallout from new weight loss medications like Novo Nordisk’s Wegovy and Ozempic […]
Read More
Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
As new weight loss medications garnered buzz last year, analysts’ forecasts signaled these drugs would be blockbusters, with some of the highest estimates calling for peak sales of at least $100 billion. In recent days, the expectations are moving higher still. The initial projections were made before Wall Street saw the results of Novo Nordisk’s […]
Read More
Wager in opposition to America’s enjoy for junk food stuff? Morgan Stanley sees hard periods forward for snack stocks like Hostess
J.M. Smucker ‘s prepare to obtain Twinkies -maker Hostess Models is a risky shift, if Morgan Stanley’s most current investigate is appropriate. The company revisited its August call that a new course of body weight loss medicines would hamper expansion at some foodstuff and beverage firms . This time it backed up its thesis with […]
Read More
Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here’s what we know
An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on 06 August, 2023. Jaap Arriens | Nurphoto | Getty Images Heather Le Biller shed 9 pounds within the first week of taking Novo Nordisk‘s blockbuster diabetes drug Ozempic – and then even more as she continued treatment. Le Biller, a […]
Read More
Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion
Ozempic drug to treat diabetes. Courtesy: Ozempic In their most recent earnings reports, Novo Nordisk and Eli Lilly proved why they are the undisputed heavyweights in the prizefight for control of the rapidly growing weight-loss medications market. Beyond staggering sales figures for Novo’s Ozempic and Wegovy and Lilly’s Mounjaro, news of a study showing Wegovy […]
Read More
Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won’t hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren’t buying it. Medical device stocks have been falling session after session, prompting UBS analyst Danielle Antalffy on Wednesday to lower her price targets for Dexcom and a […]
Read More
Your boarding go and body weight, you should: Why airways are asking passengers to move on the scales
Commencing Monday, passengers traveling on Korean Air may well be questioned to phase on a scale in advance of boarding their flight. The exercising, which will last about a few months, is essential by regulation and applies to all Korean flag carriers, a Korean Air agent advised CNBC. The legislation involves airlines to weigh travellers […]
Read More
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
Liselotte Sabroe | Afp | Getty Images Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio. The deal is Novo Nordisk’s latest attempt to capitalize on the weight loss industry gold rush, which began […]
Read More